Overview
On 28 February 2020, orphan designation EU/3/20/2247 was granted by the European Commission to IQVIA RDS Ireland Limited, Ireland, for 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide monohydrate (also known as CPI-0610) for the treatment of myelofibrosis.
Key facts
Active substance |
2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide monohydrate
|
Intented use |
Treatment of myelofibrosis
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/20/2247
|
Date of designation |
28/02/2020
|
Sponsor |
MorphoSys AG
|
Update history
Date | Update |
---|---|
December 2021 | The sponsorship was transfered to MorphoSys AG, Germany. |
June 2020 | The sponsorship was transferred to AdRes EU B.V Netherlands. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: